Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709598 | 0.87 | GHSR (0.58) | GHSRMEN1KMT2A | |
| SCHEMBL1709634 | 0.86 | GHSR (0.56) | GHSRCCR4 | |
| SCHEMBL1709621 | 0.81 | GHSR (0.56) | GHSRCCR4 | |
| SCHEMBL1709615 | 0.81 | GHSR (0.61) | GHSRADRA1ACCR4TP53CYP1A2 | |
| SCHEMBL10121926 | 0.79 | GHSR (0.67) | GHSRADRA1ACCR4CYP1A2TSHR | |
| SCHEMBL1709708 | 0.79 | GHSR (0.67) | GHSRADRA1ACCR4CYP1A2CYP2D6 | |
| SCHEMBL10121964 | 0.79 | GHSR (0.69) | GHSRADRA1ACCR4CYP1A2CYP3A4 | |
| SCHEMBL1709649 | 0.78 | GHSR (0.68) | GHSRADRA1ACCR4CYP1A2CYP3A4 | |
| SCHEMBL1988495 | 0.78 | GHSR (0.62) | GHSRADRA1ACCR4TP53MEN1 | |
| SCHEMBL1709559 | 0.77 | GHSR (0.67) | GHSRADRA1ACCR4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885ADRA1A 3128/4885CCR4 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.